News Image

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

By Mill Chart

Last update: Apr 29, 2024

These stocks are gapping in today's session

Today's gap up stocks

TickerChangeComment
DCPH72.08%DECIPHERA PHARMACEUTICALS IN's (NASDAQ:DCPH) shares rose 72.08% to $25.21 with a gap of 69.61% during Monday's session. The company is releasing earnings today. Earlier today the company had a press release: DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders.
CAUD70.85%COLLECTIVE AUDIENCE INC's (NASDAQ:CAUD) stock price increased by 70.85% to $0.67 with a gap of 27.71%. Shareholders saw the stock price going 37.7% lower in the past month.
SLNO36.24%In today's session, SOLENO THERAPEUTICS INC's (NASDAQ:SLNO) stock experienced a notable rise of 36.24%, reaching $51.62 with a significant 21.11% gap. The stock is trading 68.25% higher than 6 months ago.
PHG32.65%KONINKLIJKE PHILIPS NVR- NY's (NYSE:PHG) shares soared 32.65% to $27.95 in Monday's session, displaying an impressive 31.39% gap. KONINKLIJKE PHILIPS NVR- NY released earnings Yesterday.
SINT32.43%SINTX TECHNOLOGIES INC's (NASDAQ:SINT) shares surged 32.43% to $0.05 with a remarkable gap of 9.52%. The stock is trading 86.52% lower than 3 months ago.
IBRX24.9%During Monday's session, IMMUNITYBIO INC's (NASDAQ:IBRX) stock price showed a remarkable increase of 24.9%, reaching $9.18 with a notable 7.62% gap. In the last month the stock gained 36.87%.
BTOG18.98%During Monday's session, BIT ORIGIN LTD's (NASDAQ:BTOG) stock price showed a remarkable increase of 18.98%, reaching $3.95 with a notable 7.78% gap. The stock is trading 27.53% lower than 3 months ago.
PAHC17.36%PHIBRO ANIMAL HEALTH CORP-A's (NASDAQ:PAHC) shares rose 17.36% to $14.94 with a gap of 6.0%. Yesterday the company had a press release: Zoetis to Sell Medicated Feed Additive Portfolio to Phibro Animal Health.
MULN16.95%MULLEN AUTOMOTIVE INC's (NASDAQ:MULN) shares soared 16.95% to $3.7 during Monday's session, accompanied by a significant gap of 2.54%. A press release (California Issues HVIP Approval, Granting Mullen’s Class 3 EV Trucks a $45,000 Cash Voucher Per Vehicle Sold) was released earlier today.
HTLF16.78%During Monday's session, HEARTLAND FINANCIAL USA INC's (NASDAQ:HTLF) stock price showed a remarkable increase of 16.78%, reaching $41.72 with a notable 11.45% gap. NASDAQ:HTLF is releasing earnings today. Earlier today the company had a press release: HTLF Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Heartland Financial, USA Inc. Is Fair to Shareholders.

For the full gap up stocks list go to our gap up stocks screener.

Today's top gap down stocks

TickerChangeComment
IONM-27.66%Today, ASSURE HOLDINGS CORP's (NASDAQ:IONM) stock experienced a 27.66% fall to $0.5 with a 62.13% gap. In the last month the stock gained 42.07%.
ATXI-23.06%AVENUE THERAPEUTICS INC's (NASDAQ:ATXI) shares fell 23.06% to $4.77 during Monday's session with a gap of 47.05%. Earlier today the company had a press release: Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds.
CJJD-19.43%CHINA JO-JO DRUGSTORES HOLDI's (NASDAQ:CJJD) shares experienced a 19.43% decline to $2.28 during Monday's session, accompanied by a 32.99% gap. Shareholders saw the stock price going 22.44% lower in the past 3 months.
RWODR-17.5%In today's session, REDWOODS ACQUISITION-RIGHTS's (NASDAQ:RWODR) stock witnessed a 17.5% fall to $0.23 with a 20.32% gap. Shareholders saw the stock price going 75.0% higher in the past 3 months.
ANVS-16.71%Today, ANNOVIS BIO's (NYSE:ANVS) stock experienced a 16.71% fall to $15.0 with a 19.67% gap. Earlier today the company had a press release: Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease.
FFIE-16.38%FARADAY FUTURE INTELLIGENT E's (NASDAQ:FFIE) shares fell 16.38% to $0.04 with a gap of 26.92%. In the last month the stock lost 53.0%.
AQST-14.25%AQUESTIVE THERAPEUTICS INC's (NASDAQ:AQST) shares recorded a 14.25% decline to $3.49, with a notable 23.52% gap during today's session. Earlier today the company had a press release: Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film.
ISUN-13.33%ISUN INC's (NASDAQ:ISUN) shares fell 13.33% to $0.15 with a gap of 23.68%. Shareholders saw the stock price going 32.8% lower in the past month.
SLS-13.05%Unfavorable news for SELLAS LIFE SCIENCES GROUP I's (NASDAQ:SLS) stock! It witnessed a 13.05% decline to $1.27 in today's session, along with a 22.33% gap. In the last month the stock gained 44.55%.
VIVK-12.59%In today's session, VIVAKOR INC's (NASDAQ:VIVK) stock price decreased by 12.59% to $1.18, exhibiting a 26.39% gap. Shareholders saw the stock price going 70.84% higher in the past month.

Our gap down stocks screener will show you the full list.

Back

SELLAS LIFE SCIENCES GROUP I

NASDAQ:SLS (5/17/2024, 7:26:41 PM)

After market: 1.48 +0.02 (+1.37%)

1.46

-0.01 (-0.68%)

SLS News

News Image5 days ago - InvestorPlaceSLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024

SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the first quarter of 2024.

News Image5 days ago - BusinessInsiderSLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips SELLAS Life Sciences Gr (NASDAQ:SLS) just reported results for the first quarte...

News Image5 days ago - SELLAS Life Sciences Group, Inc.SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML)...

News Image19 days ago - SELLAS Life Sciences Group, Inc.SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant...

News Image21 days ago - ChartmillWhich stocks are experiencing notable movement on Monday?

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

News Image21 days ago - ChartmillThe market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

These stocks are gapping in today's session

News Image21 days ago - SELLAS Life Sciences Group, Inc.SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients...

News Image2 months ago - InvestorPlaceSLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023

SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image2 months ago - BusinessInsiderSLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips SELLAS Life Sciences Gr (NASDAQ:SLS) just reported results for the fourth quart...

News Image2 months ago - SELLAS Life Sciences Group, Inc.SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100%...

News Image2 months ago - GenFleet TherapeuticsGenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced it...

News Image2 months ago - SELLAS Life Sciences Group, Inc.SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April -

SLS Links
Follow us for more